Abbott Laboratories has announced that the European Union's Committee for Proprietary Medicinal Products (CPMP) has completed ITS review of the safety and efficacy data for Sibutramine (marketed in the Middle East as Reductil), and issued a positive opinion reaffirming its favorable risk/benefit profile in the treatment of obesity.
"As a physician who treats obese patients, the conclusion that sibutramine is safe and effective for the treatment of obesity is consistent with my own experience using sibutramine in treating this disease," said Dr. Stephan Rössner, head of the Obesity Unit, Huddinge University Hospital, Stockholm, Sweden.
"Obesity is an international epidemic. It contributes significantly to the onset of other serious medical conditions such as diabetes, cardiovascular diseases, cancer and respiratory conditions. Reductil, when used in combination with diet and exercise, is an important tool in my practice that helps treat obesity," he addad.
To date, more than 8.5 million people in more than 70 countries have used sibutramine for the management of obesity. Reductil is the most extensively studied prescription medication currently available for the treatment of obesity, according to a company press release.
Abbott Laboratories is a global health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritionals and medical products, including devices and diagnostics. The company employs approximately 70,000 people and markets its products in more than 130 countries. — (menareport.com)
© 2002 Mena Report (www.menareport.com)
